Article

Kinase Inhibitor Pulldown Assay (KiP) for Clinical Proteomics

2022-10-14

Abstract excerpt

<h4>ABSTRACT</h4> Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential, but current approaches are inadequate. For breast cancer treatment for example, the identification and quantification of the protein kinase ERBB2 is critical for therapeutic decisions. While immunohistochemistry (IHC) is the current clinical diag...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 225645f7-6c3f-57a6-a5e0-bedf7e960daf
DOI: 10.1101/2022.10.13.511593

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Kinase Inhibitor Pulldown Assay (KiP) for Clinical ProteomicsDOI 10.1101/2022.10.13.511593Read

Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugsSemantic proximity Read

Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapiesSemantic proximity Read

Targeting the Breast Cancer KinomeSemantic proximity Read

Pan-cancer proteogenomic investigations identify post-transcriptional kinase targetsSemantic proximity Read

Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase InhibitorsSemantic proximity Read

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read

Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative ProteomicsSemantic proximity Read

diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction ProfilingSemantic proximity Read

Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous diseaseSemantic proximity Read

SILAKin: A novel high throughput SILAC and mass spectrometry-based assay to identify the substratome of kinases secreted by pathogensSemantic proximity Read

Mining the tumor phosphoproteome for cancer markers.Semantic proximity Read

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read